Owen A J, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A
Department of Medicine (Neurology), University of Saskatchewan, Saskatoon, Canada.
Brain Res. 1997 Oct 3;770(1-2):115-22. doi: 10.1016/s0006-8993(97)00789-0.
Brief periods of global cerebral ischemia are known to produce characteristic patterns of neuronal injury both in human studies and in experimental animal models. Ischemic damage to vulnerable areas such as the CA1 sector of the hippocampus is thought to result from excitotoxic amino acid neurotransmission. The objective of this study was to determine the ability of a novel sodium channel blocking compound, zonisamide, to reduce neuronal damage by preventing the ischemia-associated accumulation of extracellular glutamate. Using a gerbil model, animals were subjected to 5 min ischemic insults. Both pre- and post-ischemic drug administration (zonisamide 150 mg/kg) were studied. Histological brain sections were prepared using a silver stain at 7 and 28 days post ischemia. The animals sacrificed at 28 days also underwent behavioral testing using a modified Morris water maze. In vivo microdialysis was performed on a separate group of animals in order to determine the patterns of ischemia-induced glutamate accumulation in the CA1 sector of the hippocampus. Pyramidal cell damage scores in the CA1 region of the hippocampus were significantly reduced in animals pre-treated with zonisamide compared to saline-treated controls, both at 7 days (drug pre-treated: 0.812 +/- 0.28, n = 8; controls: 1.625 +/- 0.24, n = 8; *P < 0.05) and 28 (drug pre-treated: 0.833 +/- 0.22, n = 12; controls: 1.955 +/- 0.26, n = 11; **P < 0.01) days post ischemia. However, animals receiving zonisamide post-treatment did not display significant differences from controls. Behavioral studies also showed significant preservation of function in drug-treated animals. Microdialysis studies confirmed a reduction in glutamate release in drug-treated animals compared to saline-treated controls. Our data suggest that zonisamide is effective in reducing neuronal damage by a mechanism involving decreased ischemia-induced extracellular glutamate accumulation and interruption of excitotoxic pathways.
在人体研究和实验动物模型中,短暂的全脑缺血已知会产生特征性的神经元损伤模式。海马体CA1区等易损区域的缺血性损伤被认为是由兴奋性氨基酸神经传递引起的。本研究的目的是确定一种新型钠通道阻断化合物唑尼沙胺通过防止与缺血相关的细胞外谷氨酸积累来减少神经元损伤的能力。使用沙鼠模型,对动物进行5分钟的缺血性损伤。研究了缺血前和缺血后给药(唑尼沙胺150mg/kg)的情况。在缺血后7天和28天使用银染法制备脑组织切片。在28天时处死的动物还使用改良的莫里斯水迷宫进行了行为测试。对另一组动物进行体内微透析,以确定海马体CA1区缺血诱导的谷氨酸积累模式。与生理盐水处理的对照组相比,唑尼沙胺预处理的动物在缺血后7天(药物预处理组:0.812±0.28,n = 8;对照组:1.625±0.24,n = 8;*P < 0.05)和28天(药物预处理组:0.833±0.22,n = 12;对照组:1.955±0.26,n = 11;**P < 0.01)时,海马体CA1区的锥体细胞损伤评分显著降低。然而,缺血后接受唑尼沙胺治疗的动物与对照组没有显著差异。行为学研究还表明,药物治疗的动物功能有显著保留。微透析研究证实,与生理盐水处理的对照组相比,药物治疗的动物谷氨酸释放减少。我们的数据表明,唑尼沙胺通过减少缺血诱导的细胞外谷氨酸积累和中断兴奋性毒性途径的机制有效减少神经元损伤。